Print Friendly, PDF & Email

NCT/Study#

NCT03218683 /

D6910C00001

A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study To Assess The Safety, Tolerability, Pharmacokinetics And Preliminary Antitumor Activity Of Ascending Doses Of AZD5991 In Subjects With Relapsed Or Refractory Haematologic Malignancies

DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: